Manufacturing & Packaging

Growth of CDMO's Pennsylvania facility will feature increase in cold chain storage capacity

Acquisition expands high-potent capabilities, along with oral development and manufacturing capacity

Division will operate under SCHOTT Pharma AG & Co. KGaA

CDMO’s new project focuses on addressing needs in oncology sector

New property is valued at $323 million

Center will feature a $1.4 billion investment plan

Production capacity for the contract manufacturer is expected to more than triple

Will benefit CDMO’s Denmark and Texas locations

With a cost of approximately $514 million, expected completion is 2026

Cheshire facility will offer plasmid DNA production, CGT development

Marks the CDMO’s second plant in the country

Containers to potentially be operational by next year, 2024 at the latest

CDMO looks to combat cancer at lower doses

Agency will be reviewing laboratory study and CMC data on the bivalent jab that targets two strains of the SARS-CoV-2 virus

CDMO’s Costa Mesa location can start tackling oncology and rare disease treatment

Partnership aims to compare reproducibility and comparability between different suspension bioreactors

New service offering is GMP compliant, with single-use fermentation capacity of up to 300 L

Focus on operational excellence is playing a major role in this effort, company says

CDMO’s Ireland campus will increase in capacity by 50% as a result

Will serve as a hub, as company aims for growth in the European region

GMP facility allows for an increase in AAV vector production

A conversation with EY life sciences leaders Jim Welch and Jay Welsh

The packaging and shipping of dangerous goods (DG) adds further challenges to the distribution pressures brought about by the pandemic

The crucial link of labeling and packaging in the pharma supply chain has its glory, but is not without its set of obstacles amid current market and global challenges

Project is expected to grow CRDO’s capacity by over 150,000 square feet

Facility, with expected completion of 2025, will specialize in mRNA-based therapies

As a result of new production area, India site’s total production capacity rises from 3 to 4.5 billion doses

Investment will grow manufacturing capabilities at Winchester site

East Syracuse site will serve as a hub for company’s US biologics CDMO business

Among functions, 80,000 square-foot space will house a 'Center of Excellence'